Sharma East India Hosp and Medical Research (BSE 524548)₹81.87−3.56%Healthcare Service Provider
In the Mar 2026 quarter (standalone), Sharma East India Hosp and Medical Research reported sales of ₹7.48 Cr, up 25.3% from Mar 2025, and net profit of ₹0.44 Cr, up 15.8% year on year. For the year to Mar 2026, sales were ₹35.95 Cr and net profit ₹1.25 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 5.50 | 5.35 | 5.84 | 1.79 | 6.73 | 9.01 | 8.16 | 5.97 | 9.48 | 9.37 | 9.60 | 7.48 |
| Expenses | 4.70 | 4.63 | 4.96 | 6.14 | 5.87 | 7.92 | 7.30 | 5.18 | 8.56 | 8.45 | 8.86 | 6.47 |
| Operating Profit | 0.81 | 0.73 | 0.89 | −4.32 | 0.87 | 1.10 | 0.85 | 0.80 | 0.91 | 0.93 | 0.75 | 1.00 |
| OPM % | 14.8% | 13.8% | 15.3% | −240.6% | 12.7% | 12.2% | 10.5% | 13.5% | 9.7% | 10.0% | 7.9% | 13.5% |
| Other Income | 0.00 | 0.00 | 0.00 | 5.32 | 0.00 | 0.05 | 0.05 | 0.24 | 0.05 | 0.06 | 0.06 | 0.03 |
| Interest | 0.27 | 0.21 | 0.30 | 0.13 | 0.16 | 0.24 | 0.14 | 0.13 | 0.10 | 0.09 | 0.12 | 0.15 |
| Depreciation | 0.35 | 0.35 | 0.36 | 0.47 | 0.36 | 0.45 | 0.37 | 0.68 | 0.43 | 0.44 | 0.44 | 0.45 |
| Profit before tax | 0.19 | 0.17 | 0.23 | 0.37 | 0.33 | 0.45 | 0.38 | 0.22 | 0.42 | 0.45 | 0.24 | 0.42 |
| Tax % | 55.0% | −61.2% | 0.0% | 89.4% | 26.4% | 26.0% | 25.6% | −60.9% | 25.5% | 28.2% | 27.9% | 0.0% |
| Net Profit | 0.11 | 0.30 | 0.24 | 0.05 | 0.26 | 0.35 | 0.30 | 0.38 | 0.33 | 0.33 | 0.19 | 0.44 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 17.22 | 17.13 | 15.99 | 14.72 | 16.18 | 8.14 | 17.02 | 20.72 | 18.50 | 29.86 | 35.95 | 35.93 |
| Expenses | 16.35 | 15.52 | 14.56 | 14.11 | 14.26 | 8.80 | 14.81 | 17.44 | 20.43 | 26.23 | 32.34 | 32.34 |
| Operating Profit | 0.87 | 1.62 | 1.45 | 0.65 | 1.92 | −0.65 | 2.26 | 3.29 | −1.87 | 3.65 | 3.62 | 3.59 |
| OPM % | 5.1% | 9.5% | 9.1% | 4.3% | 11.9% | −8.2% | 13.2% | 15.9% | −10.2% | 12.2% | 10.1% | 10.0% |
| Other Income | 0.23 | 0.27 | 0.08 | 1.12 | 0.04 | 2.84 | 0.07 | 0.07 | 5.32 | 0.32 | 0.17 | 0.20 |
| Interest | 0.47 | 1.07 | 0.72 | 0.87 | 1.14 | 0.68 | 0.69 | 1.17 | 0.94 | 0.71 | 0.50 | 0.46 |
| Depreciation | 0.60 | 0.71 | 0.63 | 0.53 | 0.44 | 0.66 | 0.79 | 1.40 | 1.49 | 1.85 | 1.73 | 1.76 |
| Profit before tax | 0.02 | 0.10 | 0.17 | 0.34 | 0.37 | 0.82 | 0.82 | 0.78 | 0.99 | 1.40 | 1.55 | 1.53 |
| Tax % | 33.3% | 27.2% | 27.7% | 22.8% | 18.4% | 24.0% | 18.0% | −5.1% | 33.9% | 12.0% | 20.5% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.89 | 0.00 | 2.58 | 0.00 | 0.00 | 5.00 | 0.12 | 0.00 | — |
| Net Profit | 0.04 | 0.09 | 0.14 | 0.28 | 0.32 | 0.65 | 0.69 | 0.84 | 0.67 | 1.25 | 1.25 | 1.29 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4.15 | 4.15 | 4.15 | 4.15 | 4.15 | 4.15 | 4.15 | 4.15 | 4.15 | 4.15 | 4.15 | 4.15 |
| Reserves | 2.03 | 2.06 | 3.32 | 3.47 | 3.73 | 4.13 | 4.78 | 5.46 | 6.41 | 7.09 | 8.35 | 9.59 |
| Borrowings | 5.97 | 6.48 | 7.51 | 5.39 | 10.90 | 7.42 | 5.99 | 4.36 | 8.30 | 5.05 | 2.27 | 7.31 |
| Other Liabilities | 2.35 | 2.67 | 2.64 | 3.26 | 3.33 | 4.14 | 3.96 | 5.08 | 4.82 | 8.86 | 12.89 | 11.87 |
| Total Liabilities | 14.50 | 15.36 | 17.62 | 16.27 | 22.11 | 19.84 | 18.88 | 19.05 | 23.68 | 25.15 | 27.66 | 32.92 |
| Fixed Assets | 6.55 | 5.99 | 6.37 | 6.04 | 4.71 | 4.39 | 5.49 | 6.83 | 9.06 | 7.67 | 9.33 | 8.42 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.02 | 0.34 | 1.73 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.30 | 0.30 | 1.78 | 1.78 | 1.79 | 1.88 | 1.88 | 1.88 | 2.04 | 2.04 | 2.04 | 2.04 |
| Other Assets | 7.65 | 9.07 | 9.47 | 8.43 | 15.27 | 11.84 | 11.51 | 10.34 | 12.58 | 15.44 | 16.29 | 22.46 |
| Inventories | 0.12 | 0.64 | 0.61 | 0.63 | 0.61 | 0.61 | 0.55 | 0.45 | 0.51 | 0.67 | 3.16 | 3.19 |
| Trade receivables | 2.10 | 2.73 | 2.33 | 3.26 | 3.46 | 4.74 | 2.67 | 3.38 | 4.30 | 2.59 | 6.55 | 11.45 |
| Cash & equivalents | 0.12 | 0.16 | 0.13 | 0.19 | 5.16 | 0.14 | 2.22 | 0.28 | 0.70 | 0.52 | 0.46 | 0.46 |
| Total Assets | 14.50 | 15.36 | 17.62 | 16.27 | 22.11 | 19.84 | 18.88 | 19.05 | 23.68 | 25.15 | 27.66 | 32.92 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | −0.19 | −0.13 | 0.81 | 3.11 | −1.42 | 1.20 | 1.39 | 2.02 | 1.27 | −1.12 | 6.68 | −3.85 |
| Cash from investing activity | −0.01 | 0.00 | −0.76 | −0.24 | 1.64 | −1.49 | 2.78 | −2.10 | −3.62 | 5.16 | −3.25 | −0.64 |
| Cash from financing activity | −0.80 | 0.18 | −0.09 | −2.81 | 4.75 | −4.75 | −2.15 | −1.77 | 2.76 | −4.19 | −3.49 | 4.53 |
| Net cash flow | −1.02 | 0.04 | −0.02 | 0.05 | 4.95 | −5.02 | 2.02 | −1.85 | 0.40 | −0.16 | −0.05 | 0.00 |
| Capex | 0.49 | 0.54 | 0.77 | 0.27 | 0.56 | 1.49 | 0.35 | 2.11 | 3.63 | 1.54 | 3.75 | 0.79 |
| Free cash flow | −0.69 | −0.67 | 0.04 | 2.85 | 0.21 | −0.28 | 4.17 | −0.08 | −2.35 | 4.00 | 3.34 | −4.64 |
| CFO / OP % | −6.0% | −14.1% | 52.9% | 218.0% | −212.1% | 65.9% | −232.1% | 95.9% | 38.9% | 44.9% | 188.9% | −95.1% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 46 | 57 | 48 | 73 | 84 | 106 | 119 | 72 | 75 | 50 | 79 | 115 |
| Inventory days | 18 | 74 | — | 100 | — | — | 218 | 50 | 43 | 227 | 212 | 82 |
| Days payable | 138 | 121 | — | 144 | — | — | 481 | 391 | 305 | 1,659 | 418 | 103 |
| Cash conversion cycle | −75 | 10 | 49 | 29 | 85 | 107 | −144 | −269 | −188 | −1,383 | −127 | 95 |
| Working capital days | 101 | 28 | 22 | 20 | −74 | 48 | 49 | 37 | −2 | −115 | 4 | 17 |
| ROCE % | 8.9% | 4.1% | 8.6% | 6.5% | 1.6% | 8.9% | −8.3% | 10.6% | 12.0% | −18.6% | 12.8% | 11.6% |
For the Mar 2026 quarter, Sharma East India Hosp and Medical Research reported sales of ₹7.48 Cr, up 25.3% year on year and net profit of ₹0.44 Cr, up 15.8% year on year. The operating margin was 13.5%.
Sharma East India Hosp and Medical Research's sales for the year to Mar 2026 were ₹35.95 Cr; over the last twelve months they were ₹35.93 Cr.
Net profit for the year to Mar 2026 was ₹1.25 Cr, and ₹1.29 Cr over the last twelve months.
Sharma East India Hosp and Medical Research reported borrowings of ₹7.31 Cr at Mar 2026, against cash and equivalents of ₹0.46 Cr.
Cash from operations was −₹3.85 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹4.64 Cr.